Long-term platinum retention after platinum-based chemotherapy in testicular cancer survivors: a 20-year follow-up study.
OBJECTIVE
Evaluation of long-term platinum (Pt) retention in testicular cancer survivors (TCSs) treated with platinum-based chemotherapy to elucidate possible mechanisms of developing late effects.


METHODS
458 TCSs treated 1980-1994 participated in a national follow-up study (2007-2008). Four treatment groups were evaluated for long-term serum Pt levels: surgery (n=135), cumulative cisplatin≤850 mg (n=252), cisplatin>850 mg (n=57) and carboplatin (n=14).


RESULTS
The median observation time was 20 (range=13-28) years. The median Pt level according to treatment group was: surgery, 50 ng/l; cisplatin≤850 mg, 85 ng/l; cisplatin>850 mg, 106 ng/l; carboplatin, 40 ng/l. The risk for having a Pt level in the highest quartile was positively associated with cisplatin dose (Ordinal regression (OR)=1.29, per 100 mg increase in cisplatin dose, 95% Confidence interval (CI)=1.20-1.38), and negatively associated with follow-up time (OR=0.50 per 5-year increase in follow-up time, 95% CI=0.37-0.68).


CONCLUSIONS
Pt levels are significantly elevated in serum at a median of 20 years after cisplatin-based chemotherapy for testicular cancer.
Institute of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway Department of Oncology, University Hospital of North Norway, Tromsø, Norway line.v.hjelle@uit.no.
Line V
LV
Hjelle
Department of Clinical Pharmacology, St. Olav Hospital, University Hospital, Trondheim, Norway.
Per O M
PO
Gundersen
Department of Oncology, Oslo University Hospital, Oslo, Norway.
Jan
J
Oldenburg
Department of Oncology, Haukeland University Hospital, Bergen, Norway.
Marianne
M
Brydøy
The Cancer Clinic, St. Olav Hospital, University Hospital, Trondheim, Norway.
Torgrim
T
Tandstad
Department of Community Medicine, UiT The Arctic University of Norway, Tromsø, Norway.
Tom
T
Wilsgaard
Division of Cancer Medicine and Radiotherapy, Rikshospitalet University Hospital, Oslo, Norway Medical Faculty, University of Oslo, Oslo, Norway.
Sophie D
SD
Fosså
Institute of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway Department of Oncology, University Hospital of North Norway, Tromsø, Norway.
Roy M
RM
Bremnes
Institute of Clinical Medicine, UiT The Arctic University of Norway, Tromsø, Norway Department of Oncology, University Hospital of North Norway, Tromsø, Norway.
Hege S
HS
Haugnes
D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D016190:Carboplatin / Q000627:therapeutic use; D002945:Cisplatin / Q000627:therapeutic use; D005500:Follow-Up Studies; D006801:Humans; D008297:Male; D008875:Middle Aged; D010984:Platinum / Q000097:blood*; D013736:Testicular Neoplasms / Q000188:drug therapy* / Q000378:metabolism / Q000401:mortality
D010984:Platinum; D016190:Carboplatin; D002945:Cisplatin
Platinum retention; cisplatin; follow-up; testicular cancer